The AMOTL1 Knockout HT29 Polyclonal Cells are a polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma epithelial line, engineered via CRISPR/Cas9-mediated disruption of the AMOTL1 gene. This loss-of-function model preserves polyclonal diversity, avoiding clonal artifacts, and provides a robust system for interrogating AMOTL1-dependent signaling pathways in intestinal epithelial biology and colorectal cancer.
The HT29 parental cell line originates from a primary colorectal adenocarcinoma of a 44-year-old female and retains the ability to undergo enterocytic differentiation under defined conditions. It is a widely accepted model of human intestinal epithelium, employed in investigations of colorectal tumorigenesis, epithelial barrier integrity, and polarized cell behavior, offering a disease-relevant and physiologically meaningful cellular context.
AMOTL1 functions as a junctional adaptor protein that localizes to tight junctions and the subapical actin cytoskeleton, where it scaffolds critical components of the Hippo signaling pathway. It directly interacts with LATS1/2 kinases, AMOT, AMOTL2, NF2/Merlin, Patj, and E-cadherin, and sequesters the transcriptional co-activators YAP and TAZ in the cytoplasm. Through these interactions, AMOTL1 integrates upstream signals from cell density, mechanical cues, and serum factors to regulate Hippo pathway output. Disruption of AMOTL1 relieves cytoplasmic sequestration of YAP/TAZ, enabling their nuclear translocation and association with TEAD1?C4 transcription factors, which drives expression of genes that promote cell proliferation and migration. This process is further linked to altered phosphorylation of YAP/TAZ and disassembly of tight junction proteins such as occludin and ZO-1.
In the HT29 background, knockout of AMOTL1 disrupts apical?Cbasal polarity and tight junction architecture, resulting in hyperactivation of YAP/TAZ-dependent transcriptional programs that mimic key hallmarks of colorectal cancer progression, including enhanced motility and uncontrolled cell growth. The intrinsic capacity of HT29 cells for enterocytic differentiation makes this polyclonal knockout system particularly suited for dissecting the crosstalk between Hippo signaling, epithelial barrier function, and malignant transformation in a human intestinal setting.
These cells are applicable to a breadth of experimental approaches: studying Hippo pathway regulation in colorectal cancer, characterizing tight junction dynamics and epithelial permeability, and screening for chemical or genetic inhibitors of AMOTL1-mediated oncogenic signaling. Representative downstream assays include western blotting for phosphorylated and total YAP/TAZ, immunofluorescence detection of occludin and ZO-1, transwell migration/invasion assays, TEAD-responsive luciferase reporters, transepithelial electrical resistance (TEER) measurements, and transcriptomic profiling via RNA-seq. For further details, please contact Ascent Research.
